Name: Vedolizumab 12371750
SKU: 08000962_12371750
Price: 292.50 EUR
Availability: InStock

Entyvio® / Vedolizumab

Drug name	Entyvio®
INN	Vedolizumab
API type	Vedolizumab is a humanised IgG1 monoclonal antibody produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Pharmacotherapeutic group	Immunosuppressants, selective immunosuppressants
ATC code	L04AA33
Target of antibody	α4β7 integrin
General function	Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. Entyvio is also indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist
Short description
Pharmacodynamic properties (Mechanism of action; Source EMA document)	Vedolizumab is a gut-selective immunosuppressive biologic. It is a humanised monoclonal antibody that binds specifically to the α4β7 integrin, which is preferentially expressed on gut homing T helper lymphocytes. By binding to α4β7 on certain lymphocytes, vedolizumab inhibits adhesion of these cells to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), but not to vascular cell adhesion molecule-1 (VCAM-1). MAdCAM-1 is mainly expressed on gut endothelial cells and plays a critical role in the homing of T lymphocytes to tissues within the gastrointestinal tract. Vedolizumab does not bind to, nor inhibit function of, the α4β1 and αEβ7 integrins.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)	The single and multiple dose pharmacokinetics of vedolizumab have been studied in healthy subjects and in patients with moderate to severely active ulcerative colitis or Crohn’s disease
Original license holder
Marketing authorisation numbers	EU/1/14/923/002
Marketing authorisation holder	Takeda Pharma A/S Delta Park 45 2665 Vallensbaek Strand Denmark
Name of the manufacturer of the biological active substance	AbbVie Bioresearch Center 100 Research Drive Worcester, MA 01605-4314 USA; Abbvie Biotechnology, Ltd Road #2 Km 59.2 PO Box 2191 Barceloneta Puerto Rico 00617; Lonza Biologics, Inc. 101 International Drive Portsmouth NH 03801 USA
Name and address of the manufacturer(s) responsible for batch release	Delpharm Novara S.r.l. Via Crosa, 86 28065 Cerano (NO) Italy; Takeda Austria GmbH St. Peter-Straße 25 4020 Linz Austria
Max shelf life	24 months
Storage conditions	2 °C-8 °C
List of excipients	Citric acid monohydrate - Sodium citrate dihydrate - L-histidine - L-histidine monohydrochloride - L-arginine hydrochloride - Polysorbate 80 - Water for injections

Vedolizumab

Therapeutic Vedolizumab antibody from the original Entyvio® commercial drug.

Not looking for Vedolizumab?

Search our therapeutic molecules product database

Entyvio® / Vedolizumab